Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA

Angelini closed its $4.1 billion deal for Catalyst Pharmaceuticals (NASDAQ:CPRX), valuing the company at about 9 times estimated 2026 EBITDA. NEW YORK, July 15, 2026, 10:06 EDT Catalyst wrapped up…